5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

5-fluorouracil (5-FU) is a standard of care in frail/elderly patients with an unresectable colorectal adenocarcinoma (CRC) in first-line setting. Panitumumab plus Sotorasib are promising in advanced line in KRAS G12C mutated CRC. In this study, We assess the safety and efficacy of 5FU combination with Panitumumab and Sotorasib as first-line treatment in frail/elderly patients with unresectable KRAS G12C mutated CRC

NCT Number	NCT07124884
Lead Sponsor	Federation Francophone de Cancerologie Digestive Collaborators: Northwest Oncology Cooperative Group(GONO), Arbeitsgemeinschaft fur Internistische Onkologie, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Conditions	Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer
Enrollment	300 participants
Start Date	2025-08-31
Primary Completion	2030-06-30 (estimated)
Study Completion	2030-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-08-15